(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-1.16%) $1.619
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Quarter results tomorrow
(bmo 2024-04-29)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands...
Stats | |
---|---|
本日の出来高 | 70 820.00 |
平均出来高 | 92 922.00 |
時価総額 | 134.31B |
EPS | €0 ( 2024-01-30 ) |
次の収益日 | ( €0 ) 2024-04-29 |
Last Dividend | €0.410 ( 2023-07-27 ) |
Next Dividend | €0 ( N/A ) |
P/E | 69.96 |
ATR14 | €0.0470 (0.20%) |
ボリューム 相関
Pfizer Inc 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Pfizer Inc 相関 - 通貨/商品
Pfizer Inc 財務諸表
Annual | 2023 |
収益: | €58.50B |
総利益: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2023 |
収益: | €58.50B |
総利益: | €33.54B (57.34 %) |
EPS: | €0.380 |
FY | 2022 |
収益: | €100.33B |
総利益: | €65.99B (65.77 %) |
EPS: | €5.63 |
FY | 2021 |
収益: | €81.29B |
総利益: | €50.47B (62.08 %) |
EPS: | €3.95 |
Financial Reports:
No articles found.
Pfizer Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
€0.400 (N/A) |
€0.400 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0.410 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
€0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | €0.325 | 2008-01-11 |
Last Dividend | €0.410 | 2023-07-27 |
Next Dividend | €0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 68 | -- |
Total Paid Out | €20.64 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.7 | -- |
Div. Sustainability Score | 6.07 | |
Div.Growth Potential Score | 4.08 | |
Div. Directional Score | 5.07 | -- |
Year | Amount | Yield |
---|
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
ZEG.DE | Ex Dividend Knight | 2023-08-10 | Semi-Annually | 0 | 0.00% | |
GDX.DE | Ex Dividend Knight | 2023-10-05 | Quarterly | 0 | 0.00% | |
PPX.DE | Ex Dividend Knight | 2023-05-02 | Semi-Annually | 0 | 0.00% | |
BC8.DE | Ex Dividend Knight | 2023-05-26 | Annually | 0 | 0.00% | |
I93.F | Ex Dividend Junior | 2023-08-28 | Quarterly | 0 | 0.00% | |
SMHN.DE | Ex Dividend Junior | 2023-06-01 | Annually | 0 | 0.00% | |
COP.DE | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% | |
LAR.DE | Ex Dividend Knight | 2023-09-12 | Quarterly | 0 | 0.00% | |
UNP.DE | Ex Dividend Knight | 2023-08-30 | Quarterly | 0 | 0.00% | |
EBO.DE | Ex Dividend Junior | 2023-05-16 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0367 | 1.500 | 9.27 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00947 | 1.200 | 9.68 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0222 | 1.500 | -0.864 | -1.296 | [0.1 - 1] |
payoutRatioTTM | 4.31 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 0.907 | 0.800 | -0.467 | -0.373 | [1 - 3] |
quickRatioTTM | 0.583 | 0.800 | -1.279 | -1.023 | [0.8 - 2.5] |
cashRatioTTM | 0.0597 | 1.500 | -0.779 | -1.169 | [0.2 - 2] |
debtRatioTTM | 0.313 | -1.500 | 4.79 | -7.18 | [0 - 0.6] |
interestCoverageTTM | 0.551 | 1.000 | -0.907 | -0.907 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.57 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.796 | -1.500 | 6.82 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.479 | 1.000 | 5.36 | 5.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0208 | 1.000 | -1.584 | -1.584 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.123 | 1.000 | -0.429 | -0.429 | [0.2 - 2] |
assetTurnoverTTM | 0.258 | 0.800 | -1.612 | -1.289 | [0.5 - 2] |
Total Score | 6.07 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 66.39 | 1.000 | 3.39 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0222 | 2.50 | -0.555 | -1.296 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.856 | 2.00 | 9.71 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 6.48 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.555 | 2.00 | 9.48 | 10.00 | [0 - 30] |
payoutRatioTTM | 4.31 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | -2.39 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.149 | 1.000 | 8.78 | 0 | [0.1 - 0.5] |
Total Score | 4.08 |
Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。